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The recruitment of leukocytes to injured tissue is crucial
for the initiation of inflammatory responses as well as for
immune surveillance to fight tumor progression. Here we
show that oncostatin M, a member of the interleukin-6-
type cytokine family and potent pro-inflammatory
cytokine stimulates the expression of the chemokines
CCL1, CCL7 and CCL8 in primary human dermal fibrob-
lasts at a faster kinetic than IL-1 or TNF. The production of
CCL1 and CCL8 is important for migration of monocytes,
while specific antibodies against CCL1 additionally
inhibit the migration of T lymphocytes. We identify the
mitogen-activated protein kinases ERK1/2 and p38 as cru-
cial factors for the enhanced expression of CCL1 and
CCL8. Depletion of the ERK1/2 target genes c-Jun or c-Fos
strongly decreases CCL1 and CCL8 expression, while p38
MAPK prolongs the half-life of CCL1, CCL7 and CCL8
mRNA through inhibition of tristetraprolin. None of the
STAT transcription factors STAT1, STAT3 or STAT5 stimu-
late transcription of CCL1 or CCL8. However, we identify
a negative regulatory function of activated STAT5 for the
gene expression of CCL1. Importantly, not STAT5 itself,
but its target gene CIS is required for the STAT5 inhibitory
effect on CCL1 expression. Finally, we show that constitu-
tive activation of STAT5 through a mutated form of JAK2
(JAK2 V617F) occurring in patients with myeloprolifera-
tive disorders similarly suppresses CCL1 expression.
Taken together, we identify novel important inflamma-
tory target genes of OSM, which are independent of STAT
signaling per se, but depend on MAPK activation and are
partly repressed through STAT5-dependent expression of
CIS.
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